Duration of dual antiplatelet therapy in acute coronary syndrome

Simon John Wilson, David E. Newby*, Dana Dawson, John Irving, Colin Berry

*Corresponding author for this work

Research output: Contribution to journalReview article

18 Citations (Scopus)
6 Downloads (Pure)

Abstract

Despite a large volume of evidence supporting the use of dual antiplatelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Clinical trials have varied markedly in the duration of therapy, both across and within trials. Recent systematic reviews and meta-analyses suggest that shorter durations of dual antiplatelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations. These findings did not show significant heterogeneity according to whether patients had stable or unstable coronary heart disease. Moreover, the potential hazards and benefits may differ when applied to the general broad population of patients encountered in everyday clinical practice who have markedly higher bleeding and atherothrombotic event rates. Clinicians lack definitive information regarding the duration of therapy in patients with acute coronary syndrome and risk scores do not appear to be sufficiently robust to address these concerns. We believe that there is a pressing need to undertake a broad inclusive safety trial of shorter durations of therapy in real world populations of patients with acute coronary syndrome. The clinical evidence would further inform future research into strategies for personalised medicine.

Original languageEnglish
Pages (from-to)573-580
Number of pages8
JournalHeart
Volume103
Issue number8
Early online date1 Mar 2017
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Journal Article
  • Review

Fingerprint Dive into the research topics of 'Duration of dual antiplatelet therapy in acute coronary syndrome'. Together they form a unique fingerprint.

  • Cite this